{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:18:16Z","timestamp":1788175096908,"version":"build-2803163510"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Limited information is available on patients with non-systemic juvenile idiopathic arthritis (nsJIA) receiving biologics in Japan. The types of biologics, treatment duration, prior and concomitant treatments, administration routes (intravenous [IV] or subcutaneous [SC] injection), and patient characteristics were investigated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We investigated nsJIA, excluding psoriatic arthritis and ankylosing spondylitis, using data from a Japanese hospital claims database (2008\u20132024).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 4191 nsJIA patients in the database, 965 (23.0%) received one or more biologics. For the first biologic, the most common were antitumour necrosis factor (anti-TNF) drugs (55.3% overall; adalimumab SC, 32.1%; etanercept SC, 9.8%; infliximab IV, 9.2%; others, &amp;lt;\u20092.1% each), followed by anti-interleukin-6 (anti-IL-6) drugs (39.9% overall; tocilizumab, 39.1% [IV, 32.4%; SC, 6.6%]; others, \u2264\u20090.7%), abatacept IV or SC (3.7%), and canakinumab SC (1.0%). Of the patients receiving anti-TNF and anti-IL-6 drugs, 40% and 58% continued treatment for \u22651\u00a0year, respectively. The most common conventional synthetic disease-modifying antirheumatic drug (csDMARD) administered prior to anti-TNF and anti-IL-6 drugs was methotrexate [39.0% (anti-TNF) and 33.5% (anti-IL-6)], with others at \u2264\u20093.6%. The most common csDMARD used concomitantly was also methotrexate [66.9% (anti-TNF) and 50.4% (anti-IL-6)], with others &amp;lt;\u20098.6%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study describes the real-world usage of biologics for nsJIA in Japan.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/mr\/roag025","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T13:02:56Z","timestamp":1773234176000},"page":"826-836","source":"Crossref","is-referenced-by-count":1,"title":["Real-world use of biologics for non-systemic juvenile idiopathic arthritis: Information from a Japanese hospital claims database"],"prefix":"10.1093","volume":"36","author":[{"given":"Takashi","family":"Funatogawa","sequence":"first","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Mii","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saki","family":"Katayama","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Aoki","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuaki","family":"Matsubara","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Kojima","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Hoshiba","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"2026083106413757500_ref1","first-page":"390","article-title":"International League of Associations for Rheumatology. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"2026083106413757500_ref2","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(07)60363-8","article-title":"Juvenile idiopathic arthritis","volume":"369","author":"Ravelli","year":"2007","journal-title":"Lancet."},{"key":"2026083106413757500_ref3","volume-title":"Japan Intractable Diseases Information Center (in Japanese)"},{"key":"2026083106413757500_ref4","volume-title":"JCR Guideline for the Treatment of Juvenile Idiopathic Arthritis 2024\u201325 (in Japanese)","author":"Japan College of Rheumatology","year":"2025"},{"key":"2026083106413757500_ref5","volume-title":"Guide to Support Patients with Juvenile Idiopathic Arthritis Part I: For Medical Staff (in Japanese)","author":"Japan College of Rheumatology","year":"2023"},{"key":"2026083106413757500_ref6","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Pediatric rheumatology collaborative study group (PRCSG). Etanercept in children with polyarticular juvenile rheumatoid arthritis","volume":"342","author":"Lovell","year":"2000","journal-title":"N Engl J Med"},{"key":"2026083106413757500_ref7","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa0706290","article-title":"Pediatric rheumatology collaborative study group (PRCSG) and paediatric rheumatology international trials organisation (PRINTO). Adalimumab with or without methotrexate in juvenile rheumatoid arthritis","volume":"359","author":"Lovell","year":"2008","journal-title":"N Engl J Med"},{"key":"2026083106413757500_ref8","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.22838","article-title":"A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis","volume":"56","author":"Ruperto","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2026083106413757500_ref9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/annrheumdis-2016-210456","article-title":"Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial","volume":"77","author":"Brunner","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2026083106413757500_ref10","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","article-title":"Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial","volume":"372","author":"Ruperto","year":"2008","journal-title":"Lancet"},{"key":"2026083106413757500_ref11","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1136\/annrheumdis-2014-205351","article-title":"Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial","volume":"74","author":"Brunner","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2026083106413757500_ref12","article-title":"Real-world use of biologics for systemic juvenile idiopathic arthritis: information from a Japanese hospital claims database","volume":"36","author":"Funatogawa","year":"2025","journal-title":"Mod Rheumatol"},{"key":"2026083106413757500_ref13"},{"key":"2026083106413757500_ref14","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/acr.20460","article-title":"2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features","volume":"63","author":"Beukelman","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026083106413757500_ref15","volume-title":"Guide to the Use of Biologics in Juvenile Idiopathic Arthritis (JIA) 2020 Edition (in Japanese)","author":"Pediatric Rheumatology Association of Japan, Japan College of Rheumatology","year":"2020"},{"key":"2026083106413757500_ref16","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/art.42037","article-title":"2021 American College of Rheumatology guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis","volume":"74","author":"Onel","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2026083106413757500_ref17","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S2665-9913(20)30025-4","article-title":"Frequency of biologic switching and the outcomes of switching in children and young people with juvenile idiopathic arthritis: a national cohort study","volume":"2","author":"Kearsley-Fleet","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2026083106413757500_ref18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12969-022-00682-x","article-title":"Real-world data reveals the complexity of disease modifying anti-rheumatic drug treatment patterns in juvenile idiopathic arthritis: an observational study","volume":"20","author":"Grazziotin","year":"2022","journal-title":"Pediatr Rheumatol Online J"},{"key":"2026083106413757500_ref19","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12969-023-00897-6","article-title":"Biologic switching patterns among children with non-systemic juvenile idiopathic arthritis","volume":"21","author":"Pedersen","year":"2023","journal-title":"Pediatr Rheumatol Online J"},{"key":"2026083106413757500_ref20","doi-asserted-by":"crossref","first-page":"980","DOI":"10.24953\/turkjped.2023.22","article-title":"Choice and switch of biologic drugs in juvenile idiopathic arthritis","volume":"65","author":"\u015eener","year":"2023","journal-title":"Turk J Pediatr"},{"key":"2026083106413757500_ref21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12969-019-0318-5","article-title":"Clinical features and characteristics of uveitis associated with juvenile idiopathic arthritis in Japan: first report of the pediatric rheumatology association of Japan (PRAJ)","volume":"17","author":"Yasumura","year":"2019","journal-title":"Pediatr Rheumatol Online J"},{"key":"2026083106413757500_ref22","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/art.40884","article-title":"2019 American College of Rheumatology\/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis","volume":"71","author":"Ringold","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2026083106413757500_ref23","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1093\/rheumatology\/keac587","article-title":"Biologics with or without methotrexate in treatment of polyarticular juvenile idiopathic arthritis: effectiveness, safety and drug survival","volume":"62","author":"Thiele","year":"2023","journal-title":"Rheumatology (Oxford)"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roag025\/67339771\/roag025.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/5\/826\/67339771\/roag025.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/5\/826\/67339771\/roag025.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T10:41:52Z","timestamp":1788172912000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/36\/5\/826\/8519320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":23,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,3,13]]},"published-print":{"date-parts":[[2026,8,31]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roag025","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,3,13]]}}}